Comparative pharmacology of adrenergic α2C receptors coupled to Ca2+ signaling through different Gα proteins

Neurochemistry International

Volumn 55, Issue 7, 2009, Pages 467-475

  Kurko, Dalma ^a   Bekes, Zsófia ^a   Gere, Anikó ^a   Baki, Andrea ^a   Boros, András ^a   Kolok, Sándor ^a   Bugovics, Gyula ^a   Nagy, József ^a   Szombathelyi, Zsolt ^a   Ignácz Szendrei, Györgyi ^a  

^a GEDEON RICHTER LTD   (Hungary)

Author keywords

2C AR; Chimeric G qi5 protein; Fluorometric Ca2+ assay; High throughput screening; Promiscuosus G 16 protein

Indexed keywords

1,3,4,5',6,6',7,12B OCTAHYDRO 1',3' DIMETHYL 2H SPIRO[BENZO[B]FURO[2,3 A]QUINOLIZINE 2,4' PYRIMIDINE] 2' ONE; ADRENALIN; ALPHA 1 ADRENERGIC RECEPTOR; ALPHA 2 ADRENERGIC RECEPTOR; ALPHA 2 ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; ALPHA 2C ADRENERGIC RECEPTOR; AMINO ACID; BETA ADRENERGIC RECEPTOR; BRIMONIDINE; CHIMERIC PROTEIN; CLONIDINE; CYCLIC AMP; FORSKOLIN; GUANINE NUCLEOTIDE BINDING PROTEIN ALPHA SUBUNIT; LIGAND; MOXONIDINE; NORADRENALIN; OXYMETAZOLINE; RECOMBINANT RECEPTOR; YOHIMBINE;

ANIMAL CELL; ARTICLE; ASSAY; BINDING AFFINITY; CALCIUM MOBILIZATION; CALCIUM SIGNALING; CALCIUM TRANSPORT; CELL LINE; COST EFFECTIVENESS ANALYSIS; DRUG RESEARCH; DRUG TARGETING; FLUOROMETRY; HIGH THROUGHPUT SCREENING; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RELIABILITY; SCREENING;

ADRENERGIC ALPHA-AGONISTS; ANIMALS; CALCIUM; CALCIUM SIGNALING; CHO CELLS; CRICETINAE; CRICETULUS; CYCLIC AMP; FLUOROMETRY; FORSKOLIN; GTP-BINDING PROTEIN ALPHA SUBUNITS, GQ-G11; GTP-BINDING PROTEINS; HUMANS; QUINOXALINES; RADIOLIGAND ASSAY; RATS; RECEPTORS, ADRENERGIC, ALPHA-2; RECEPTORS, G-PROTEIN-COUPLED; RECOMBINANT PROTEINS; RNA, MESSENGER; TRANSFECTION;

EID: 69349099591     PISSN: 01970186     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuint.2009.04.015     Document Type: Article

References (95)

1. 2+ channels in axotomized rat sensory neurons. J. Neurosci. 17 (1997) 1633-1641
2. Arnsten A.F. The biology of being frazzled. Science 280 (1998) 1711-1712
3. 2a-adrenoceptor agonists. Neurochem. Int. 51 5 (2007) 268-276
4. 2-adrenergic receptors. Fed. Am. Soc. Exp. Biol. J. 6 3 (1992) 832-839
5. Bylund D.B. Alpha-2 adrenoceptor subtypes: are more better?. Br. J. Pharmacol. 144 (2005) 159-160
6. Calzada B.C., and Artinano A.A. Alpha-adrenoceptor subtypes. Pharmacol. Res. 44 3 (2001) 195-208
7. Cerione R.A. Reconstitution of receptor/GTP-binding protein interactions. Biochim. Biophys. Acta 1071 4 (1991) 473-501
8. Chambers C., Smith F., Williams C., Marcos S., Liu Z.H., Hayter P., Ciaramella G., Keighley W., Gribbon P., and Sewing A. Measuring intracellular calcium fluxes in high throughput mode. Comb. Chem. High Throughput Screen. 6 (2003) 355-362
9. 50) of an enzymatic reaction. Biochem. Pharmacol. 22 (1973) 3099-3108
10. qα mutational activation and coupling to receptors and phospholipase. J. Biol. Chem. 267 (1992) 31-34
11. iα. Nature 363 (1993) 274-276
12. sα that alter the fidelity of receptor activation. Mol. Pharmacol. 50 (1996) 885-890
13. Coward P., Chan S.D.C., Wada H.G., Humphries G.M., and Conklin B.R. Chimeric G proteins allow a high-throughput signaling assay of Gi-coupled receptors. Anal. Biochem. 270 (1999) 242-248
14. Crassous P.A., Denis C., Paris H., and Sénard J.M. Interest of alpha2-adrenergic agonists and antagonists in clinical practice: background, facts and perspectives. Curr. Top. Med. Chem. 7 2 (2007) 187-194
15. Dauzenberg F.M., Higelin J., Pflieger P., Neidhart W., and Guba W. Estabilishment of robust functional assays for the characterization of neuropeptide Y (NPY) receptors: identification of 3-(5-benzoyl-thiazol-2-yamino)-benzonitrile as selective NPY type 5 receptor antagonist. Neuropharmacology 48 (2005) 1043-1055
16. 2-adrenoceptors. Eur. J. Pharmacol. 361 (1998) 1-15
17. Downey P.M., Lozza G., Petrò R., Diodato E., Foglia C., Bottazzoli F., Brusa R., Asquini T., Reggiani A., and Grilli M. Ecdysone-based system for controlled inducible expression of metabotropic glutamate receptor subtypes 2, 5, and 8. J. Biomol. Screen. 10 8 (2005) 841-848
18. 2C2 adrenergic receptors to Gi and Gs. J. Biol. Chem. 267 (1992) 15795-15801
19. 2-adrenergic receptor subtype coupling to Gs. Mol. Pharmacol. 45 (1994) 696-702
20. Eglen R.M. Functional G protein-coupled receptor assays for primary and secondary screening. Comb. Chem. High Throughput Screen. 8 (2005) 311-318
21. 2-adrenoceptor activation. Neurochem. Int. 51 1 (2007) 47-56
22. Gabriel D., Vernier M., Pfeifer M.J., Dasen B., Tenaillon L., and Bouhelal R. High throughput screening technologies for direct cyclic AMP measurement. Assay Drug Dev. Technol. 1 2 (2003) 291-303
23. αq/i proteins: characterization of new antagonists. Mol. Pharmacol. 50 (1996) 923-930
24. Görnemann T., von Wenckstern H., Kleuser B., Villalón C.M., Centurión D., Jähnichen S., and Pertz H.H. Characterization of the postjunctional alpha 2C-adrenoceptor mediating vasoconstriction to UK14304 in porcine pulmonary veins. Br. J. Pharmacol. 151 2 (2007) 186-194
25. 2-adrenoceptor subtypes in gastric mucosal defense in the rat. Neurochem. Int. 51 5 (2007) 289-296
26. Hieble J.P., Bondinell W.E., and Ruffolo Jr. R.R. Alpha- and beta-adrenoceptors: from the gene to the clinic. 1. Molecular biology and adrenoceptor subclassification. J. Med. Chem. 38 18 (1995) 3415-3444
27. 2-Adrenoceptor agonists stimulate high-affinity GTPase activity in a receptor subtype-selective manner. Eur. J. Pharmacol. 374 (1999) 137-146
28. 35S]GTPγS binding. Biochem. Pharmacol. 55 7 (1998) 1035-1043
29. Jeon Y.T., Luoa C., Forrayb C., Vaysseb P.J.J., Branchekb T.A., and Gluchowskia C. Pharmacological evaluation of UK-14,304 analogs at cloned human α adrenergic receptors. Bioorg. Med. Chem. Lett. 5 19 (1995) 2255-2258
30. Ji T.H., Grossmann M., and Ji I. G protein-coupled receptors. I. Diversity of receptor-ligand interactions. J. Biol. Chem. 273 28 (1998) 17299-17302
31. Kable J.W., Murrin L.C., and Bylund D.B. In vivo gene modification elucidates subtype-specific functions of alpha(2)-adrenergic receptors. J. Pharmacol. Exp. Ther. 293 1 (2000) 1-7
32. Kamibayashi T., and Maze M. Clinical uses of alpha2-adrenergic agonists. Anesthesiology 93 5 (2000) 1345-1349
33. Kassack M.U., Hofgen B., Lehmann J., Eckstein N., Quillan J.M., and Sadee W. Functional screening of G protein-coupled receptors by measuring intracellular calcium with a fluorescence microplate reader. J. Biomol. Screen. 7 (2002) 233-246
34. 2-Adrenoceptor subtypes-unexpected functions for receptors and ligands derived from gene-targeted mouse models. Neurochem. Int. 51 5 (2007) 277-281
35. 16 the optimal tool for fishing ligands of orphan G protein-coupled receptors?. Trends Pharmacol. Sci. 22 11 (2001) 560-564
36. Kostenis E., Degtyarev M.Y., Conklin B.R., and Wess J. The N-terminal extension of Gαq is critical for constraining the selectivity of receptor coupling. J. Biol. Chem. 272 (1997) 19107-19110
37. Kostenis E., Waelbroeck M., and Milligan G. Techniques: promiscuous Gα proteins in basic research and drug discovery. Trends Pharmacol. Sci. 26 11 (2005) 595-602
38. Kowal D., Nawoschik S., Ochalski R., and Dunlop J. Functional calcium coupling with the human metabotropic glutamate receptor subtypes 2 and 4 by stable co-expression with a calcium pathway facilitating G-protein chimera in Chinese hamster ovary cells. Biochem. Pharmacol. 66 5 (2003) 785-790
39. Kowal D., Zhang J., Nawoschik S., Ochalski R., Vlattas A., Shan Q., Schechter L., and Dunlop J. The C-terminus of Gi family G-proteins as a determinant of 5-HT(1A) receptor coupling. Biochem. Biophys. Res. Commun. 294 3 (2002) 655-659
40. ++ elevation in Chinese hamster ovary cells. J. Pharmacol. Exp. Ther. 287 2 (1998) 667-671
41. Lakhlani P.P., MacMillan L.B., Guo T.Z., McCool B.A., Lovinger D.M., Maze M., and Limbird L.E. Substitution of a mutant alpha (2a)-adrenergic receptor via hit and run gene targeting reveals the role of this subtype in sedative, analgesic, and anesthetic sparing responses in vivo. Proc. Natl. Acad. Sci. U.S.A. 94 (1997) 9950-9955
42. Lalchandani S.G., Lei L., Zheng W., Suni M.M., Moore B.M., Liggett S.B., Miller D.D., and Feller D.R. Yohimbine dimers exhibiting selectivity for the human alpha 2C-adrenoceptor subtype. J. Pharmacol. Exp. Ther. 303 3 (2002) 979-984
43. Langer S.Z. Presynaptic autoreceptors regulating transmitter release. Neurochem. Int. 52 1-2 (2008) 26-30
44. Lazareno S., and Birdsall N.J.M. Estimation of competitive antagonist affinity from functional inhibition curves using the Gaddum, Schild and Cheng-Prusoff equations. Br. J. Pharmacol. 109 (1993) 1110-1119
45. Limbird L.E. Receptors linked to inhibition of adenylate cyclase: additional signaling mechanisms. Fed. Am. Soc. Exp. Biol. J. 2 (1988) 2686-2695
46. Link R., Daunt D., Barsh G., Chruscinski A., and Kobilka B. Cloning of two mouse genes encoding alpha 2-adrenergic receptor subtypes and identification of a single amino acid in the mouse alpha2-C10 homolog responsible for an interspecies variation in antagonist binding. Mol. Pharmacol. 42 1 (1992) 16-27
47. Liu A.M., Ho M.K., Wong C.S., Chan J.H., Pau A.H., and Wong Y.H. Galpha(16/z) chimeras efficiently link a wide range of G protein-coupled receptors to calcium mobilization. J. Biomol. Screen. 8 (2003) 39-49
48. Liu J., Conklin B.R., Blin N., Yun J., and Wesss J. Identification of a receptor/G-protein contact site critical for signaling specificity and G-protein activation. Proc. Natl. Acad. Sci. U.S.A. 92 (1995) 11642-11646
49. MacDonald E., Kobilka B.K., and Scheinin M. Gene targeting-homing in on the α2-adrenoceptor-subtype function. Trends Pharmacol. Sci. 18 (1997) 211-219
50. Marchese A., George S.R., Kolakowski Jr. L.F., Lynch K.R., and O'Dowd B.F. Novel GPCRs and their endogenous ligands: expanding the boundaries of physiology and pharmacology. Trends Pharmacol. Sci. 20 (1999) 370-375
51. Maze M., and Fujinaga M. Alpha(2) adrenoceptors in pain modulation-which subtype should be targeted to produce analgesia?. Anesthesiology 92 (2000) 934-936
52. Millan M.J. Descending control of pain. Prog. Neurobiol. 66 6 (2002) 355-474
53. 35S]GTPγS binding assays. Trends Pharmacol. Sci. 24 (2003) 87-90
54. Milligan G., Marshall F., and Rees S. G16 as a universal G protein adapter: implications for agonist screening strategies. Trends Pharmacol. Sci. 17 7 (1996) 235-237
55. Milligan G., and Rees S. Chimaeric Gα proteins: their potential use in drug discovery. Trends Pharmacol. Sci. 20 (1999) 118-124
56. i-coupled receptors. Mol. Pharmacol. 57 (2000) 13-23
57. 2+-back to basics. Trends Pharmacol. Sci. 26 4 (2005) 218-223
58. qo5. Biochem. Pharmacol. 68 (2004) 761-772
59. Munk S.A., Gluchowski C., Dolby L., Wong H., Burke J., Kharlamb A., Manlapaz C., Padillo E., Rodgers D., Ohta B., Wheeler L., and Garst M. Analogues of UK 14,304 as R2-adrenoceptor agonists. Twist and agent polarity as design elements. Bioorg. Med. Chem. Lett. 4 (1994) 459-462
60. 2C-adrenergic receptors. Bioorg. Med. Chem. Lett. 15 (2005) 2758-2760
61. New D.C., and Wong Y.H. Chimeric and promiscuous G proteins in drug discovery and the deorphanization of GPCRs. Drug Des. Rev. Online 2 (2005) 66-79
62. 16 couple a wide variety of receptors to phospholipase C. J. Biol. Chem. 270 25 (1995) 15175-15180
63. 2C-adrenoceptors in human neuroblastoma SH-SY5Y cells. Eur. J. Pharmacol. 372 (1999) 109-115
64. 15 fusion proteins: evidence for multiple ligand-activation binding sites. Br. J. Pharmacol. 130 (2000) 1505-1512
65. Pauwels P.J., and Colpaert F.C. Partial to complete antagonism by puative antagonists at wild-type α2C-adrenoceptors based on kinetics analyses of agonist: antagonist interactions. Br. J. Pharmacol. 131 (2000) 1385-1390
66. 2A-adrenoceptor activity by both single amino acid mutation (Thr373Lys) and Gαo protein co-expression: evidence for inverse agonism. J. Pharmacol. Exp. Ther. 292 (2000) 654-663
67. Perez D. From plants to man: the GPCR "Tree of life". Mol. Pharmacol. 67 (2005) 1383-1384
68. 2-adrenergic receptor subtype diversity: one receptor is not enough. Am. J. Physiol.: Regul. Integr. Comp. Physiol. 283 (2002) 287-295
69. 2-adrenoceptor subtypes with cytosensor microphysiometry. Eur. J. Pharmacol. 385 2-3 (1999) 247-253
70. 2-adrenoceptor subtypes. J. Pharmacol. Exp. Ther. 279 (1996) 694-702
71. 2-Adrenoceptor regulation of adenylyl cyclase in CHO cells: dependence on receptor density, receptor subtype and current activity of adenylyl cyclase. Eur. J. Pharmacol. 335 (1997) 53-63
72. 1-adrenoceptors. Br. J. Pharmacol. 129 7 (2000) 1339-1346
73. Ruffolo Jr. R.R., Bondinell W., and Hieble J.P. Alpha- and beta-adrenoceptors: from the gene to the clinic. 2. Structure-activity relationships and therapeutic applications. J. Med. Chem. 38 19 (1995) 3681-3716
74. Ruffolo Jr. R.R., and Hieble J.P. α-Adrenoceptors. Pharmacol. Ther. 61 (1994) 1-64
75. Ruffolo Jr. R.R., Nichols A.J., Stadel J.M., and Hieble J.P. Pharmacologic and therapeutic applications of alpha 2-adrenoceptor subtypes. Annu. Rev. Pharmacol. Toxicol. 33 (1993) 243-279
76. Sanders R.D., and Maze M. α2-Adrenoceptor agonists. Curr. Opin. Investig. Drugs 8 1 (2007) 25-33
77. Saunders C., and Limbird L.E. Localization and trafficking of α2-adrenergic receptor subtypes in cells and tissues. Pharmacol. Ther. 84 (1999) 193-205
78. Sautel M., and Milligan G. Molecular manipulation of G-protein-coupled receptors: a new avenue into drug discovery. Curr. Med. Chem. 7 9 (2000) 889-896
79. Schaak S., Cayla C., Blaise R., Quinchon F., and Paris H. HepG2 and SK-N-MC: two human models to study alpha-2 adrenergic receptors of the alpha-2C subtype. J. Pharmacol. Exp. Ther. 281 2 (1997) 983-991
80. Scholz J., and Tonner P.H. α2-Adrenoceptor agonists in anaesthesia: a new paradigm. Curr. Opin. Anaesthesiol. 13 (2000) 437-442
81. Serle J.B., Lustgarten J.S., and Podos S.M. A clinical trial of metipranodol, a noncardioselective beta-adrenergic antagonist, in ocular hypertension. Am. J. Ophthalmol. 112 (1991) 302-307
82. Shoichet B.K. Interpreting steep dose-response curves in early inhibitor discovery. J. Med. Chem. 49 (2006) 7274-7277
83. Stone L.S., Fairbanks C.A., and Wilcox G.L. Moxonidine, a mixed α2-adrenergic and imidazoline receptor agonist, identifies a novel adrenergic target for spinal analgesia. Ann. N.Y. Acad. Sci. 1009 (2003) 378-385
84. Szabo B. Imidazoline antihypertensive drugs: a critical review on their mechanism of action. Pharmacol. Ther. 93 (2002) 1-35
85. Thomsen W., Frazer J., and Unett D. Functional assays for screening GPCR targets. Curr. Opin. Biotechnol. 16 (2005) 655-665
86. Thomsen, W.J., Gatlin, J., Unett, D.J., Behan, D.P., 2004. Developing functional GPCR screens. http://www.currentdrugdiscovery.com/pdf/2004/518083.pdf.
87. 3H]-MK912 is alpha-2C selective among human alpha-2A, alpha-2B and alpha-2C adrenoceptors. J. Pharmacol. Exp. Ther. 271 3 (1994) 1558-1565
88. 3H]MK912 and subtype-selective drugs. Brain Res. 770 1-2 (1997) 261-266
89. 35S]GTPγS and cAMP functional assays. Eur. J. Pharmacol. 411 (2001) 211-221
90. Uvegas A.J., Kowal D., Zhang Y., Spangler T.B., Dunlop J., Semus S., and Jones P.G. The role of transmembrane helix 5 in agonist binding to the human H3 receptor. J. Pharmacol. Exp. Ther. 301 (2002) 451-458
91. Williams C. cAMP detection methods in HTS: selecting the best from the rest. Nat. Rev. Drug Discov. 3 (2004) 125-135
92. Wong W.C., Wang D., Forray C., Vaysse P.J.-J., Branchek T.A., and Gluchowski C.A. Convenient synthesis of 2-amino-2-oxazolines and their pharmacological evaluation at cloned human α-adrenergic receptors. Bioorg. Med. Chem. Lett. 4 (1994) 2317-2322
93. 2-adrenoceptor agonists. J. Med. Chem. 43 (2000) 1699-1704
94. Wong Y.H. Gi assays in transfected cells. Methods Enzymol. 238 (1994) 81-94
95. Yokoyama T., Katob N., and Yamada N. Development of a high-throughput bioassay to screen melatonin receptor agonists using human melatonin receptor expressing CHO cells. Neurosci. Lett. 344 (2003) 45-48